Jessica Frau1, Luisa Maria Villar2, Claudia Sardu3, Maria Antonietta Secci4, Lucia Schirru4, Diana Ferraro5, Giancarlo Coghe6, Lorena Lorefice6, Giuseppe Fenu6, Roberta Bedin5, Patrizia Sola5, Maria Giovanna Marrosu6, Eleonora Cocco6. 1. Multiple Sclerosis Center, Department of Medical Sciences and Public Health, University of Cagliari, Via Is Guadazzonis 2, 09126, Cagliari, Italy. jessicafrau@hotmail.it. 2. Immunology and Neurology Service, Multiple Sclerosis Unit, Hospital Universitario Ramón Y Cajal, Madrid, Spain. 3. Department of Medical Sciences and Public Health, University of Cagliari, Policlinico Monserrato, SS554, Monserrato, Italy. 4. Multiple Sclerosis Center of Cagliari, Via Is Guadazzonis 2, 09126, Cagliari, Italy. 5. Neurology Unit, Department of Biomedical, Metabolic and Neurosciences, University of Modena and Reggio Emilia, Modena, Italy. 6. Multiple Sclerosis Center, Department of Medical Sciences and Public Health, University of Cagliari, Via Is Guadazzonis 2, 09126, Cagliari, Italy.
Abstract
BACKGROUND: Oligoclonal IgM (OCMB) and IgG (OCGB) bands were found to be associated with poor multiple sclerosis (MS) prognosis. OBJECTIVE: We aimed to evaluate the prognostic value of OCMB/OCGB in a cohort of Sardinian MS patients. MATERIALS AND METHODS: We recruited patients from the University of Cagliari. They underwent lumbar puncture for diagnostic purposes. Demographic and the following clinical data were recorded: clinical course; time to reach EDSS 3 and 6; EDSS at last follow-up; and MS treatments. The influence of gender, clinical course, age at onset, treatments, and OCGB/OCMB on reaching EDSS 3 was analysed using Cox regression. Kaplan-Meier curves were used to study the time to reach EDSS 3 considering OCMB/OCGB and therapies. RESULTS: The enrolled number of subjects was 503. The variables influencing the achievement of EDSS 3.0 were: male gender (p = 0.005); progressive course (p = 0.001); age at onset (p < 0.001); and disease-modifying drugs (p < 0.001). The OCGB/OCMB status was not significant. Kaplan-Meier analysis showed no difference in time to reach EDSS 3 for patients with and without OCGB or OCMB in both treated and non-treated groups. CONCLUSION: Our study did not confirm the poor prognostic value of OCMB/OCGB. These results may be influenced by the peculiar genetic background associated with the risk of MS in Sardinians.
BACKGROUND: Oligoclonal IgM (OCMB) and IgG (OCGB) bands were found to be associated with poor multiple sclerosis (MS) prognosis. OBJECTIVE: We aimed to evaluate the prognostic value of OCMB/OCGB in a cohort of Sardinian MSpatients. MATERIALS AND METHODS: We recruited patients from the University of Cagliari. They underwent lumbar puncture for diagnostic purposes. Demographic and the following clinical data were recorded: clinical course; time to reach EDSS 3 and 6; EDSS at last follow-up; and MS treatments. The influence of gender, clinical course, age at onset, treatments, and OCGB/OCMB on reaching EDSS 3 was analysed using Cox regression. Kaplan-Meier curves were used to study the time to reach EDSS 3 considering OCMB/OCGB and therapies. RESULTS: The enrolled number of subjects was 503. The variables influencing the achievement of EDSS 3.0 were: male gender (p = 0.005); progressive course (p = 0.001); age at onset (p < 0.001); and disease-modifying drugs (p < 0.001). The OCGB/OCMB status was not significant. Kaplan-Meier analysis showed no difference in time to reach EDSS 3 for patients with and without OCGB or OCMB in both treated and non-treated groups. CONCLUSION: Our study did not confirm the poor prognostic value of OCMB/OCGB. These results may be influenced by the peculiar genetic background associated with the risk of MS in Sardinians.
Authors: I Boscá; M J Magraner; F Coret; J C Alvarez-Cermeño; M Simó-Castelló; L M Villar; B Casanova Journal: J Neuroimmunol Date: 2010-06-09 Impact factor: 3.478
Authors: Maristella Steri; Valeria Orrù; M Laura Idda; Maristella Pitzalis; Mauro Pala; Ilenia Zara; Carlo Sidore; Valeria Faà; Matteo Floris; Manila Deiana; Isadora Asunis; Eleonora Porcu; Antonella Mulas; Maria G Piras; Monia Lobina; Sandra Lai; Mara Marongiu; Valentina Serra; Michele Marongiu; Gabriella Sole; Fabio Busonero; Andrea Maschio; Roberto Cusano; Gianmauro Cuccuru; Francesca Deidda; Fausto Poddie; Gabriele Farina; Mariano Dei; Francesca Virdis; Stefania Olla; Maria A Satta; Mario Pani; Alessandro Delitala; Eleonora Cocco; Jessica Frau; Giancarlo Coghe; Lorena Lorefice; Giuseppe Fenu; Paola Ferrigno; Maria Ban; Nadia Barizzone; Maurizio Leone; Franca R Guerini; Matteo Piga; Davide Firinu; Ingrid Kockum; Izaura Lima Bomfim; Tomas Olsson; Lars Alfredsson; Ana Suarez; Patricia E Carreira; Maria J Castillo-Palma; Joseph H Marcus; Mauro Congia; Andrea Angius; Maurizio Melis; Antonio Gonzalez; Marta E Alarcón Riquelme; Berta M da Silva; Maurizio Marchini; Maria G Danieli; Stefano Del Giacco; Alessandro Mathieu; Antonello Pani; Stephen B Montgomery; Giulio Rosati; Jan Hillert; Stephen Sawcer; Sandra D'Alfonso; John A Todd; John Novembre; Gonçalo R Abecasis; Michael B Whalen; Maria G Marrosu; Alessandra Meloni; Serena Sanna; Myriam Gorospe; David Schlessinger; Edoardo Fiorillo; Magdalena Zoledziewska; Francesco Cucca Journal: N Engl J Med Date: 2017-04-27 Impact factor: 91.245
Authors: Luisa M Villar; María C Sádaba; Ernesto Roldán; Jaime Masjuan; Pedro González-Porqué; Noelia Villarrubia; Mercedes Espiño; José A García-Trujillo; Alfredo Bootello; José C Alvarez-Cermeño Journal: J Clin Invest Date: 2005-01 Impact factor: 14.808
Authors: N García-Barragán; L M Villar; M Espiño; M C Sádaba; P González-Porqué; J C Alvarez-Cermeño Journal: Eur J Neurol Date: 2009-03 Impact factor: 6.089
Authors: Lm Villar; N García-Barragán; M Espiño; E Roldán; Mc Sádaba; J Gómez-Rial; P González-Porqué; Jc Alvarez-Cermeño Journal: Mult Scler Date: 2007-10-17 Impact factor: 6.312
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: S Jarius; F Paul; O Aktas; N Asgari; R C Dale; J de Seze; D Franciotta; K Fujihara; A Jacob; H J Kim; I Kleiter; T Kümpfel; M Levy; J Palace; K Ruprecht; A Saiz; C Trebst; B G Weinshenker; B Wildemann Journal: Nervenarzt Date: 2018-12 Impact factor: 1.214
Authors: Marko Petržalka; Eva Meluzínová; Jana Libertínová; Hana Mojžišová; Jitka Hanzalová; Petra Ročková; Martin Elišák; Silvia Kmetonyová; Jan Šanda; Ondřej Sobek; Petr Marusič Journal: PLoS One Date: 2022-06-27 Impact factor: 3.752
Authors: Igal Rosenstein; Sofia Rasch; Markus Axelsson; Lenka Novakova; Kaj Blennow; Henrik Zetterberg; Jan Lycke Journal: Front Immunol Date: 2022-08-10 Impact factor: 8.786
Authors: Enric Monreal; Susana Sainz de la Maza; Lucienne Costa-Frossard; Paulette Walo-Delgado; Javier Zamora; José Ignacio Fernández-Velasco; Noelia Villarrubia; Mercedes Espiño; Daniel Lourido; Paloma Lapuente; Inmaculada Toboso; José Carlos Álvarez-Cermeño; Jaime Masjuan; Luisa María Villar Journal: Neurol Neuroimmunol Neuroinflamm Date: 2021-07-22
Authors: S Jarius; F Paul; O Aktas; N Asgari; R C Dale; J de Seze; D Franciotta; K Fujihara; A Jacob; H J Kim; I Kleiter; T Kümpfel; M Levy; J Palace; K Ruprecht; A Saiz; C Trebst; B G Weinshenker; B Wildemann Journal: J Neuroinflammation Date: 2018-05-03 Impact factor: 8.322
Authors: Roberta Magliozzi; Valentina Mazziotti; Luigi Montibeller; Anna I Pisani; Damiano Marastoni; Agnese Tamanti; Stefania Rossi; Francesco Crescenzo; Massimiliano Calabrese Journal: Front Cell Neurosci Date: 2020-10-16 Impact factor: 5.505